The Epstein-Barr virus (EBV) homolog of the conserved herpesvirus
glycoprotein gN is predicted to be encoded by the BLRF1 open reading frame (ORF). Antipeptide antibody to a sequence
corresponding to residues in the predicted BLRF1 ORF immunoprecipitated
a doublet of approximately 8 kDa from cells expressing the BLRF1 ORF as a recombinant protein. In addition, four glycosylated proteins of 113, 84, 48, and 15 kDa could be immunoprecipitated from virus-producing cells by the same antibody. The 15-kDa species was the mature form of
gN, which carried
2,6-sialic acid residues. The remaining glycoproteins which associated with gN were products of the
BBRF3 ORF of EBV, which encodes the EBV gM homolog. The 8-kDa doublet seen in cells expressing recombinant gN comprised precursors of the
mature 15-kDa gN. Coexpression of EBV gM with EBV gN was required for
authentic processing of the 8-kDa forms to the 15-kDa form.
 |
INTRODUCTION |
The envelopes of herpesviruses
include multiple glycoproteins which are known or inferred
to play various roles in the attachment, entry, egress, and spread of
virus. Some of these glycoproteins appear to be unique to
individual members or subfamilies of herpesviruses, presumably
reflecting adaptations to specialized biological niches; others are
more obviously conserved in either sequence or genomic organization, reflecting a common evolutionary origin, if not a current
commonality of function. By general consensus, five glycoproteins, gB, gH, gL, gN, and gM, fall under the
heading of conserved molecules, although not all have been well
characterized, even in some of the most extensively studied of
herpesviruses.
The five Epstein-Barr virus (EBV) open reading frames (ORF) that are
predicted to encode members of the conserved group of glycoproteins are BXLF2 (encoding gH), BKRF2 (encoding gL),
BALF4 (encoding gB), BLRF1 (encoding gN), and BBRF3 (encoding gM)
(1). Glycoprotein gp85, the EBV gH (8, 22),
glycoprotein gp25, the EBV gL (31), and
glycoprotein gp110, the EBV gB (6), have all
been characterized biochemically and functionally, and a mixed picture
is emerging when their behavior is compared to that of their
counterparts in other herpesviruses. The EBV gB is not a major
virion component as it is in many herpesviruses but, rather, is
localized primarily to the nuclear membrane of virion-producing cells
(5), and although in many herpesviruses gB is critical to
virus entry, in EBV it plays a major role in virus assembly (9,
14). In contrast, although the EBV gH-gL complex includes a third
poorly conserved but functionally important glycoprotein
gp42 (18), in general it behaves like that of other herpesviruses. Glycoprotein gH is retained in the endoplasmic reticulum
in the absence of its partner gL (25, 31), and the virion-associated complex plays a critical role in virus entry (7,
17, 18, 30).
Neither the gN nor the gM homologs of EBV have yet been described. All
gN homologs are predicted to be small type 1 membrane proteins. The EBV
BLRF1 ORF is predicted to encode a type 1 membrane protein of 102 amino
acids with an Mr of 10,944 without
posttranslational modification (1). The putative sequence
includes no potential N-linked glycosylation sites, but 12 of the 102 amino acids are serine or threonine residues that are predicted to lie
outside the signal sequence or carboxyl-terminal transmembrane domain and might be targets for O-linked glycosylation. Descriptions of gN
homologs in the alphaherpesviruses, however, indicate a variety of
processing differences. The pseudorabies virus (PRV) gN homolog is
a 14-kDa O-glycosylated protein which is associated with the virion
(11). The herpes simplex virus type 1 (HSV-1) homolog is a
12-kDa protein (3) that does not appear to carry posttranslational modifications (26). The bovine herpesvirus 1 homolog is a 9-kDa nonglycosylated membrane protein found on the
surface of the virion (19). It is reported to be disulfide linked to a second virion component and to be more tightly associated with the tegument than is the envelope glycoprotein
gD. The varicella-zoster virus homolog is a 7-kDa protein
which is very close to the predicted size of the molecule after
cleavage of the signal peptide and without further posttranslational
modifications (27). Most recently, the PRV gN homolog
has been shown to exist in a disulfide-linked complex with
glycoprotein gM and to be dependent on gM for localization in the virion (10).
To examine the structure and processing of the EBV gN homolog, we
expressed the protein as a recombinant molecule and compared its
biosynthesis with that of the native protein in virus. We report here
that the BLRF1 ORF of EBV encodes a 15-kDa glycoprotein which carries O-linked sugars, whose processing differs for the recombinant and the native proteins. Like all the
glycoprotein gH homologs, the EBV gN associates with and
requires the presence of a second glycoprotein for
authentic processing. As in PRV, the EBV glycoprotein gN
associates with the gM homolog, the product of the BBRF3 ORF.
 |
MATERIALS AND METHODS |
Cells.
Akata, a Burkitt lymphoma-derived cell line that
carries and can be induced to make EBV (28) (a gift of John
Sixbey, St. Jude Children's Research Hospital, Memphis, Tenn.), was
grown in RPMI 1640 (Sigma Chemical Co., St. Louis, Mo.) supplemented with 10% heat-inactivated fetal bovine serum (Gibco/BRL Life
Technologies, Grand Island, N.Y.). CV-1 cells were grown in Dulbecco's
modified Eagle's medium containing 10% heat-inactivated fetal bovine
serum.
Virus production.
EBV was obtained from Akata cells which
were resuspended at 2 × 106 per ml and induced with
100 µg of anti-human immunoglobulin G per ml for 5 days. Stocks of
vaccinia virus expressing the T7 RNA polymerase (vvT7) (21)
were grown in CV-1 cells infected at a multiplicity of infection of
0.01 and harvested by freeze-thawing and sonication of cells.
Expression in the pTM1 vector.
The BLRF1 ORF was amplified
by a PCR method from the EcoRI G fragment of Akata virus
DNA. The 5' primer (GGC GC
C ATG GGG AAG GTC CT) included
the first ATG of the ORF and an NcoI site. The 3' primer
(GGC GC
T CGA GCA TCT AAT CCG) included the BLRF1 stop
codon and an XhoI site. The DNA amplified with these primers
was cut with NcoI and XhoI and inserted into pTM1
(21) that had previously been cut with the same enzymes to
make plasmid pTM1-gN. The BBRF3 ORF was amplified from Akata virus DNA.
The 5' primer (GGC GT
C ATG AAG TCC AAG A) included the
first ATG of the ORF and a BspHI site. The 3' primer (GGC
GGA GCT
CTT AGG GGA AGA T) included the BBRF3 stop codon
and a SacI site. The DNA amplified with these primers was
cut with BspHI and SacI and inserted into pTM1
that had been cut with SacI and NcoI (which leaves ends compatible with those produced by BspHI) to make
plasmid pTM1-gM. Plasmids were transfected into CV-1 cells 30 min after the cells had been infected with vvT7. For transfections of a single
plasmid, 5 µg of DNA was mixed with 50 µl of Lipofectin (Gibco/BRL)
made up to a total volume of 800 µl with serum-free medium. For
transfections of two plasmids, the total amount of DNA used was 5 µg.
Each mixture was incubated for 45 min at room temperature before being
added to cells.
Antibodies.
Three antipeptide antibodies were made, as
described previously (22), to synthetic peptides
corresponding respectively to residues 125 to 137 of the BKRF2 ORF
(31) (anti-gL), to residues 44 to 55 and 55 to 69 of the
predicted BLRF1 ORF (anti-gN), and to residues 346 to 364 of the BBRF3
ORF (anti-gM). A cysteine residue not present in the virus sequence was
added to the amino terminus of the BBRF3 and BKRF2 peptides for ease of
coupling to keyhole limpet hemocyanin. All antibodies were purified by chromatography on protein A (Sigma) coupled to Affi-Gel-15 (Bio-Rad, Richmond, Calif.).
Radiolabeling and immunoprecipitation.
EBV was labeled
extrinsically with 125I (Amersham Corp., Arlington Heights,
Ill.) after concentration by centrifugation from 4 liters of spent
culture medium as previously described (31). EBV proteins
were labeled biosynthetically with [3H]leucine or
[3H] glucosamine (20 Ci/mmol; Amersham) for 20 h
at 6 h after induction with anti-human immunoglobulin G as
previously described (31). CV-1 cells that had been infected
with vvT7 and transfected with pTM1 DNA, pTM1-gN DNA, pTM1-gM DNA, or a
mixture of plasmids were labeled with [3H]leucine or
[3H] glucosamine as previously described
(16). Labeled cells were solubilized in
radioimmunoprecipitation buffer (50 mM Tris-HCl [pH 7.2], 0.15 M
NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% sodium dodecyl
sulfate [SDS], 0.1 mM phenylmethylsulfonyl fluoride, 100 U of
aprotinin per ml) and immunoprecipitated with antibody and protein
A-Sepharose CL4B (Sigma). Immunoprecipitated proteins were washed,
dissociated either by boiling for 2 min or by heating to 37°C for 30 min in sample buffer with or without 2-mercaptoethanol, and analyzed by
SDS-polyacrylamide gel electrophoresis in 18% acrylamide cross-linked
with 0.09% bisacrylamide or in 9 to 18% polyacrylamide cross-linked
with 0.28% N,N'-diallyltartardiamide followed by
fluorography.
Oligosaccharide digestion.
For removal of sugars,
immunoprecipitated proteins were washed in radioimmunoprecipitation
buffer and resuspended in buffer (0.1% SDS, 50 mM EDTA, 1%
2-mercaptoethanol, 100 mM sodium phosphate, 0.5%
N-octylglucoside [pH 7.2 or pH 5.0]), boiled for 2 min,
cooled, and incubated at 37°C for 20 h with the addition of
either 5 mU of neuraminidase from Newcastle disease virus or 5.0 mU of
neuraminidase from Arthrobacter, or neuraminidase and 2.5 mU
of O-glycosidase. All enzymes were from Boehringer Mannheim.
Digested samples were analyzed by SDS-polyacrylamide gel
electrophoresis and fluorography.
 |
RESULTS |
Expression of gN as a recombinant protein.
The BLRF1 ORF is
predicted to encode the gN homolog of EBV, a molecule which is
expected, without posttranslational modification, to be a protein of
approximately 10 kDa. Structural glycoproteins of EBV can
be expressed only by inducing virus in a proportion of latently
infected B cells, usually fewer than 50%, to switch from the latent to
the lytic cycle. Hence, virus proteins which are not particularly
abundant are very difficult to visualize against a background of
cellular protein synthesis. To make a preliminary identification of the
putative EBV gN, we therefore cloned the BLRF1 ORF into the pTM1 vector
for expression under the control of the strong bacteriophage T7
promoter. A rabbit antibody, anti-gN, was made to two peptides
corresponding to residues 44 through 55 and 55 through 69 of the
predicted BLRF1 sequence and used to examine the expression of pTM1-gN
in CV-1 cells that had been concurrently infected with a recombinant
vaccinia virus vvT7 that expresses the T7 polymerase. Anti-gN
immunoprecipitated a unique doublet of approximately 8 kDa from cells
that had been labeled with [3H] leucine (Fig.
1). Longer exposures of the gel revealed
the two faint bands at just above the 21.5-kDa marker and just below the 31-kDa marker to be present in cells transfected with vector alone.
In contrast, no protein was immunoprecipitated from cells that had been
labeled with [3H] glucosamine.

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 1.
Electrophoretic analysis (in 18% polyacrylamide gels)
of proteins immunoprecipitated with anti-gN from CV-1 cells transfected
with pTM1 vector or pTM1-gN, infected with vvT7 and labeled with
[3H] leucine or
[3H] glucosamine. Sizes are indicated on the
left in kilodaltons.
|
|
Expression of gN in Akata cells.
With the preliminary
identification of EBV gN as a protein slightly smaller than predicted,
perhaps as the result of posttranslational cleavage of the putative
signal peptide, the anti-gN antibody was used to look for expression in
Akata cells that had been induced with anti-immunoglobulin. The
antibody reacted with both fixed and unfixed cells in
indirect-immunofluorescence assays (18), suggesting that gN
was expressed on the cell surface (data not shown). Anti-gN but not
preimmune antibody from the same animal immunoprecipitated a doublet of
approximately 8 kDa from Akata cells that had been labeled with
[3H] leucine which was similar to that seen in CV-1
cells transfected with pTM1- gN (Fig.
2). In addition, however, a larger, more
prominent 15- kDa species was seen. Both anti-gN and preimmune
antibody nonspecifically immunoprecipitated a large number of
[3H] leucine-labeled proteins with masses greater than
approximately 30 kDa. The autoradiographs were clearer when proteins
were instead labeled with [3H] glucosamine.
The 8- kDa doublet carried no detectable sugar label. This had also
been true for the recombinant protein expressed in pTM1. However, the
15- kDa species labeled well with
[3H] glucosamine. A very long exposure of the
autoradiograph gave evidence of faint sugar labeling of the upper of
the two 8- kDa species (data not shown). Additional diffuse bands
only faintly visible with preimmune antibody were evident just above
the 45- and 66- kDa markers and at the top of the gel, although
their apparent masses were uncertain in the high percentage
polyacrylamide (18%) that had been used for optimum visualization of
low-molecular-weight proteins.

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 2.
Electrophoretic analysis in 18% polyacrylamide of
proteins immunoprecipitated from Akata cells that had been induced with
anti-immunoglobulin and labeled with
[3H] glucosamine or
[3H] leucine. Proteins were immunoprecipitated with
anti-gN or with preimmune antibody from the same rabbit. Sizes are
indicated on the left in kilodaltons.
|
|
To obtain better resolution of the higher-molecular-weight species,
proteins immunoprecipitated from Akata cells labeled with [3H] glucosamine were heated to 37°C rather
than 100°C to dissociate them from protein-A agarose and were
electrophoresed in 9 to 18% polyacrylamide. Although the
higher-molecular-weight species still ran very diffusely, producing a
smear of radioactivity throughout the gel, they were better resolved,
since at least three glycoproteins of approximately 48, 84, and 113 kDa were visible (Fig. 3). For comparative purposes, the EBV gH-gL complex, which comprises three proteins of 85, 42/38, and 25 kDa, was included in the gel.

View larger version (45K):
[in this window]
[in a new window]
|
FIG. 3.
Electrophoretic analysis in 9 to 18% polyacrylamide of
proteins immunoprecipitated from Akata cells that had been induced with
anti-immunoglobulin and labeled with
[3H] glucosamine. Proteins were
immunoprecipitated with a rabbit anti-peptide antibody to the EBV gL
(gp25), which immunoprecipitates the EBV gH-gL complex of gp85,
gp42/38, and gp25, with rabbit anti-peptide antibody anti-gN, or with
preimmune rabbit antibody. Immunoprecipitated proteins were eluted from
protein A-agarose beads by heating at 37°C. Sizes are indicated on
the left in kilodaltons.
|
|
Association of gN with gM.
The gN homologs of all other
herpesviruses studied to date are relatively small proteins. The
immunoprecipitation of such high-molecular-weight species from Akata
cells by the anti-gN antibody was thus a surprise. The very recent
observation that the PRV gN homolog associates with gM (10)
then suggested that the higher-molecular-weight species seen in Akata
cells, but not in CV-1 cells transfected with pTM1-gN alone, might be
products of the EBV gM homolog. To test the hypothesis, an anti-peptide antibody, anti-gM, was made to a peptide corresponding to residues 346 to 364 encoded by the BBRF3 ORF, which is predicted to encode EBV gM.
The anti-gM antibody immunoprecipitated proteins from induced Akata
cells labeled with [3H] glucosamine that
comigrated with the higher-molecular-weight proteins immunoprecipitated
by anti-gN (Fig. 4). A very faint band at
15 kDa comigrated with the prominent 15- kDa species
immunoprecipitated by anti-gN. In this experiment, the larger of the
doublet of proteins at 8 kDa labeled more convincingly with
[3H] glucosamine.

View larger version (63K):
[in this window]
[in a new window]
|
FIG. 4.
Electrophoretic analysis in 9 to 18% polyacrylamide of
proteins immunoprecipitated from Akata cells that had been induced with
anti-immunoglobulin and labeled with
[3H] glucosamine. Proteins were
immunoprecipitated with anti-peptide antibody anti-gN, anti-peptide
antibody anti-gM, anti-peptide antibody to EBV gL, or pre-immune
antibody. Immunoprecipitated proteins were eluted from protein
A-agarose beads by heating at 37°C. Sizes are indicated on the right
in kilodaltons.
|
|
The results of this experiment suggested that the
higher-molecular-weight species were not products of the BLRF1 ORF but, rather, represented those of the gene encoding the EBV gM homolog, the
BBRF3 ORF. To confirm this hypothesis, the BBRF3 ORF was cloned into
the pTM1 vector and expressed in CV-1 cells that were infected with
vvT7. Anti-gM immunoprecipitated the three-higher-molecular weight
glycoproteins from these cells (Fig.
5). Their mobilities did not change
appreciably if pTM1-gM were cotransfected with pTM1-gN.

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 5.
Electrophoresis in 18% polyacrylamide of proteins
immunoprecipitated with anti-gM or preimmune rabbit antibody from CV-1
cells labeled with [3H] glucosamine, infected
with vvT7, and transfected with pTM1-gM or cotransfected with pTM1-gM
and pTM1-gN. Immunoprecipitated proteins were eluted from protein
A-agarose beads by heating at 37°C. Arrows indicate three
glycoproteins specifically immunoprecipitated by anti-gM antibody.
|
|
Glycosylation of gN.
The observation that the 15- kDa
glycoprotein (gp15) was immunoprecipitated well by the
anti-gN antibody and very poorly if at all by the anti-gM antibody
suggested that although it was not apparent in CV-1 cells
transfected with pTM1-gN, it was a product of the BLRF1 ORF. Since the
product of the BLRF1 ORF is predicted to include no potential N-linked
glycosylation sites, the possible relationship of gp15 to the 8- kDa
doublet was examined by immunoprecipitating proteins with anti-gN from
induced Akata cells that had been labeled with
[3H] leucine and digesting them with neuraminidase or
neuraminidase plus O-glycanase. Digestions were done at pH
7.2 or 5.0, which is the optimum pH of the neuraminidases used.
Neuraminidase derived from Arthrobacter, which hydrolyzes
terminal
2,3-,
2,6-, and
2,8- ketosidic bonds that join
sialic acid to oligosaccharides, reduced the mass of the gp15 to that
of the 8- kDa doublet found in both Akata cells and cells
transfected with pTM1-gN (Fig. 6). No
further digestion was achieved by the addition of
O-glycosidase. The neuraminidase derived from Newcastle
disease virus cleaves
2,3- and
2,8- but not
2,6- ketosidic
bonds and was unable to alter the mobility of gp15, indicating that the
majority of the sugars on the molecule were
2,6-linked sialic acid
residues.

View larger version (70K):
[in this window]
[in a new window]
|
FIG. 6.
Electrophoretic analysis in 18% polyacrylamide of
proteins immunoprecipitated with anti-gN from induced Akata cells and
labeled with [3H] leucine. After immunoprecipitation
and before electrophoresis, the proteins were incubated overnight in
buffer at pH 7.2 or 5.0 or buffer at either pH containing neuraminidase
from Arthrobacter (na/Arth), neuraminidase and
O-glycanase (na/Arth/O-g), or neuraminidase from
Newcastle disease virus (na/NDV). Sizes are indicated on the right in
kilodaltons.
|
|
Coexpression of gN and gM facilitates authentic processing of
gp15.
The failure of the pTM1-gN product to be processed to a
15- kDa or higher-molecular-weight species in CV-1 cells and the
apparent association of gN and gM in virus-producing cells suggested
that just as gL serves as a chaperone-like protein for gH,
glycoprotein gM might be required for authentic processing
of gN. To test this hypothesis, CV-1 cells were cotransfected with
pTM1-gN and pTM1-gM. Cotransfection resulted in the appearance of the
15- kDa form of gN, which could be immunoprecipitated by anti-gN
and, less efficiently, by anti-gM (Fig.
7A). Very long exposure of the gel (data
not shown) revealed that a small amount of the incompletely processed
form of gN could also be immunoprecipitated by anti-gM. Neuraminidase
digestion of the 15- kDa species produced in cotransfected cells
reduced its mass to that of the 8- kDa doublet (Fig. 7B).

View larger version (61K):
[in this window]
[in a new window]
|
FIG. 7.
(A) Electrophoretic analysis in 18% polyacrylamide of
proteins immunoprecipitated with anti-gN or anti-gM from CV-1 cells
labeled with [3H] leucine, infected with vvT7, and
transfected with pTM1 vector alone, pTM1-gN (gN), or pTM1-gN and
pTM1-gM (gN/gM). (B) All proteins were immunoprecipitated with anti-gN
and were incubated overnight in buffer or buffer containing
neuraminidase from Arthrobacter (na/Arth) before
being subjected to electrophoresis. Sizes are indicated on the right in
kilodaltons.
|
|
Linkage of gN and gM.
The PRV gN is reported to be
disulfide linked to gM, and the BHV-1 gN is reported to be
disulfide linked to an as yet unidentified virion component.
To determine the nature of the interaction between gN and gM,
virus-producing cells that had been radiolabeled with [3H] glucosamine were immunoprecipitated with
antibodies to gN and gM and analyzed by electrophoresis under
nonreducing conditions (Fig. 8). Although
the proteins ran a little differently under nonreducing conditions,
there was no indication that higher- molecular-weight complexes
of the individual gM and gN species were formed. The EBV gH-gL complex
was included in the gel for comparative purposes. This complex is
not disulfide linked. The positions of the gN and gM species
relative to the proteins in the gH-gL complex were similar to
those seen under reducing conditions in Fig. 3, in which samples
of the same immunoprecipitates were electrophoresed, or in
Fig. 4.

View larger version (45K):
[in this window]
[in a new window]
|
FIG. 8.
Electrophoretic analysis in 9 to 18% polyacrylamide
under nonreducing conditions of proteins immunoprecipitated by
preimmune antibody, anti-peptide antibody to EBV gL, anti-gN, or
anti-gM from Akata cells that had been induced with anti-immunoglobulin
and labeled with [3H] glucosamine.
Immunoprecipitated proteins were eluted from protein A-agarose beads by
heating at 37°C. Positions of molecular size markers (in kilodaltons)
electrophoresed under reducing conditions several lanes away from the
samples are indicated on the right.
|
|
 |
DISCUSSION |
The association of glycoproteins gH and gL and the
dependence of gH on coexpression with gL for folding and intracellular transport are well- known themes in herpesvirology. The essential nature of these two proteins and their apparently conserved roles in
virus penetration provide a framework within which to accommodate such a conserved structural paradigm. It now appears, somewhat surprisingly, that two additional conserved glycoproteins,
gN and gM, which have not so far proven to be essential for replication of any herpesvirus, may follow a similar pattern.
The expression of the EBV gN homolog as a recombinant protein first
suggested that the gene product was a nonglycosylated protein that
migrated in polyacrylamide as a doublet of approximately 8 kDa. The
implication that was most consistent with predictions from the sequence
of the gene was that gN was a type 1 membrane protein from which the
signal peptide had been cleaved. Examination of the molecule in
virus-producing cells, however, suggested a somewhat different
processing pathway. The mature 15- kDa protein was
glycosylated, carrying sugars that could be removed only by a
neuraminidase that cleaves
2,6-linked sialic acid residues, and on
long exposure of autoradiographs the upper of the proteins in the
doublet also appeared to carry some sugar. This suggested that after
cleavage of the signal peptide to create the nonglycosylated smaller
protein in the doublet, the larger of the doublet proteins was
made by posttranslational addition of O-linked
N-acetylgalactosamine in the endoplasmic reticulum or
cis Golgi. This, in turn, would allow for the addition
of
2,6-linked sialic acid, possibly in the trans Golgi
apparatus (29). It further implied that gN expressed in the
pTM1 vector in the absence of other virus proteins was not completely
processed. Whether or not this represents a defect in transportation as
well is uncertain. CV-1 cells that had been transfected with pTM1-gN
alone and fixed with 4% paraformaldehyde to inactivate vaccinia virus
did react with anti-gN in indirect-immunofluorescence assays (data not
shown), but since the transfected cells were significantly damaged by
the vaccinia virus infection, some or all of this reactivity may have
been due to penetration of the cell by antibody.
The recent observation that the PRV gN associates with the PRV gM
(10) and some preliminary data with an anti-peptide antibody made to residues corresponding to the predicted sequence of the EBV gM
homolog fortunately provided some clues to the identity of the virus
protein that might be required to facilitate processing of gN. Not only
were products of the BBRF3 ORF associated with gN, but also
coexpression of gM with gN in the absence of other virus proteins was
sufficient to restore authentic gN processing.
All gM homologs are predicted to be type 3 membrane proteins with
multiple transmembrane domains (2, 23, 24). In all viruses
in which they have been studied, i.e., PRV (4), HSV- 1 (2, 20), human cytomegalovirus (12, 15) and
equine herpes virus 1 (EHV-1) (23), the proteins are virion
components that carry N-linked sugars. The EBV BBRF3 ORF is predicted
to encode a protein of approximately 46 kDa without posttranslational
modification with two potential N-linked glycosylation sites and eight
putative transmembrane domains (1). The three glycosylated
species of 48, 84, and 113 kDa probably represent differential
processing of polysaccharide chains, as is the case for the HSV-1 gM
(2) and EHV-1 gM (23), although as yet the
apparent low abundance of the protein and the availability of only a
peptide antibody for immunoprecipitation has made it impossible to
confirm the assumption. Both the EHV-1 gM (23) and the human
cytomegalovirus gM (12) are thought to aggregate because of
the very hydrophobic nature of the sequence. There was no appreciable
difference in the relative mobility of any of the EBV gM species if
they were dissociated from immunoprecipitating agarose beads at 37°C
instead of by boiling, which suggests that this may not be the case for EBV. However, another possible explanation for the apparent low abundance of the EBV gM, even when expressed as a recombinant molecule
under control of the strong T7 promoter, is that it is not being
completely solubilized by the protocols normally used to extract virus
membrane proteins.
There are both similarities and differences between the
association of the EBV and PRV gN and gM homologs. The PRV gN-gM
complex is disulfide linked (10), whereas there is little
evidence for covalent linkage of the EBV gN-gM complex. On the other
hand, transport of both PRV and EBV gN is dependent on coexpression of
gM. Although the sugars on PRV gN can be processed in the absence of
gM, it is much less efficient and the protein is not found in the
virion in a virus with expression of gM deleted. At the same time, in
neither virus does it appear that the maturation of gM is influenced by
gN. Thus, gM is found in the PRV virion in a virus with expression
of gN deleted, and no difference could be seen in the processing of
recombinant EBV gM in the presence of recombinant gN. It is not
currently possible to determine whether either gN or gM is a virion
protein in EBV. It is difficult to see even relatively abundant
proteins in purified virions harvested from spent culture media of
induced cells. Indirect immunofluorescence with the anti-gN antibody,
which, unlike anti-gM, was made against a peptide that is predicted to
be on the luminal or extracellular side of the membrane, does, however,
suggest that gN at least is present in the plasma membrane of the
virus-producing cell.
As pointed out previously (10), the report that the BHV-1 gN
homolog is disulfide linked to a 39- kDa protein that is more tightly associated with the tegument than membrane proteins known to
span the membrane only once (19) strongly suggests that
there is a gN-gM complex in this virus as well, and one in which gM is
most difficult to solubilize. To date, no essential functions have been
ascribed to either molecule in any virus, but defects in penetration
have been reported for PRV lacking gN (10) and deletion of
gN in varicella-zoster virus results in a modest reduction in syncytium
formation. Preliminary results with a recombinant EBV with expression
of gN deleted indicate that it has significantly reduced infectivity
for B lymphocytes (13). Although these effects are subtle,
they are consistent with a role for the protein at or close to the
point of membrane penetration and suggest that like gH-gL, gN-gM may
represent a second glycoprotein complex that is conserved
in both structure and function across more than one herpesvirus
subfamily.
This research was supported by Public Health Service grant
AI20662 from the National Institute of Allergy and Infectious Diseases.
| 1.
|
Baer, R.,
A. T. Bankier,
M. D. Biggin,
P. L. Deininger,
P. J. Farrell,
T. J. Gibson,
G. Hatfull,
G. S. Hudson,
S. C. Satchwell,
C. Seguin,
P. S. Tuffnell, and B. G. Barrell.
1984.
DNA sequence and expression of the B95-8 Epstein-Barr virus genome.
Nature
310:207-211[Medline].
|
| 2.
|
Baines, J. D., and B. Roizman.
1993.
The UL10 gene of herpes simplex virus 1 encodes a novel viral glycoprotein, gM, which is present in the virion and in the plasma membrane of infected cells.
J. Virol.
67:1441-1452[Abstract/Free Full Text].
|
| 3.
|
Barker, D. E., and B. Roizman.
1992.
The unique sequence of herpes simplex virus 1 L component contains an additional translated open reading frame designated UL49.5.
J. Virol.
66:562-566[Abstract/Free Full Text].
|
| 4.
|
Dijkstra, J. M.,
N. Visser,
T. C. Mettenleiter, and B. G. Klupp.
1996.
Identification and characterization of pseudorabies virus glycoprotein gM as a nonessential virion component.
J. Virol.
70:5684-5688[Abstract/Free Full Text].
|
| 5.
|
Gong, M., and E. Kieff.
1990.
Intracellular trafficking of two major Epstein-Barr virus glycoproteins, gp350/220 and gp110.
J. Virol.
64:1507-1516[Abstract/Free Full Text].
|
| 6.
|
Gong, M.,
T. Ooka,
T. Matsuo, and E. Kieff.
1987.
Epstein-Barr virus glycoprotein homologous to herpes simplex virus gB.
J. Virol.
61:499-508[Abstract/Free Full Text].
|
| 7.
|
Haddad, R. S., and L. M. Hutt-Fletcher.
1989.
Depletion of virosomes made with Epstein-Barr virus proteins abolishes their ability to fuse with virus receptor-bearing cells.
J. Virol.
63:4998-5005[Abstract/Free Full Text].
|
| 8.
|
Heineman, T.,
M. Gong,
J. Sample, and E. Kieff.
1988.
Identification of the Epstein-Barr virus gp85 gene.
J. Virol.
62:1101-1107[Abstract/Free Full Text].
|
| 9.
|
Herrold, R. E.,
A. Marchini,
S. Frueling, and R. Longnecker.
1995.
Glycoprotein 110, the Epstein-Barr virus homolog of herpes simplex virus glycoprotein B, is essential for Epstein-Barr virus replication in vivo.
J. Virol.
70:2049-2054[Abstract].
|
| 10.
|
Jöns, A.,
J. M. Dijkstra, and T. C. Mettenleiter.
1998.
Glycoproteins M and N of pseudorabies virus form a disulfide-linked complex.
J. Virol.
72:550-557[Abstract/Free Full Text].
|
| 11.
|
Jöns, A.,
H. Granzlow,
R. Kuchling, and T. C. Mettenleiter.
1996.
The UL49.5 gene of pseudorabies virus codes for an O-glycosylated structural protein of the virus envelope.
J. Virol.
70:1237-1241[Abstract].
|
| 12.
|
Kari, B.,
W. Li,
R. Cooper,
R. Goertz, and B. Radeke.
1994.
The human cytomegalovirus UL100 gene encodes the gC-II glycoproteins recognized by group 2 monoclonal antibodies.
J. Gen. Virol.
75:3081-3086[Abstract/Free Full Text].
|
| 13.
| Lake, C. M., and L. M. Hutt-Fletcher.
Unpublished data.
|
| 14.
|
Lee, S. K., and R. Longnecker.
1997.
The Epstein-Barr virus glycoprotein 110 carboxy-terminal tail domain is essential for lytic virus replication.
J. Virol.
71:4092-4097[Abstract].
|
| 15.
|
Lehner, R.,
H. Meyer, and M. Mach.
1989.
Identification and characterization of a human cytomegalovirus gene coding for a membrane protein that is conserved among human herpesviruses.
J. Virol.
63:3792-3800[Abstract/Free Full Text].
|
| 16.
|
Li, Q. X.,
C. Buranathai,
C. Grose, and L. M. Hutt-Fletcher.
1997.
Chaperone functions common to nonhomologous Epstein-Barr virus gL and varicella-zoster virus gL proteins.
J. Virol.
71:1667-1670[Abstract].
|
| 17.
|
Li, Q. X.,
M. K. Spriggs,
S. Kovats,
S. M. Turk,
M. R. Comeau,
B. Nepom, and L. M. Hutt-Fletcher.
1997.
Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes.
J. Virol.
71:4657-4662[Abstract].
|
| 18.
|
Li, Q. X.,
S. M. Turk, and L. M. Hutt-Fletcher.
1995.
The Epstein-Barr virus (EBV) BZLF2 gene product associates with the gH and gL homologs of EBV and carries an epitope critical to infection of B cells but not of epithelial cells.
J. Virol.
69:3987-3994[Abstract].
|
| 19.
|
Liang, X.,
B. Chow,
C. Raggo, and L. A. Babiuk.
1996.
Bovine herpesvirus 1 UL49.5 homolog gene encodes a novel viral envelope protein that forms a disulfide-linked complex with a second virion structural protein.
J. Virol.
70:1448-1454[Abstract].
|
| 20.
|
MacLean, C. A.,
L. M. Robertson, and F. E. Jamieson.
1991.
Characterization of the UL10 gene product of herpes simplex virus type 1 and investigations of its role in vivo.
J. Gen. Virol.
74:975-983[Abstract/Free Full Text].
|
| 21.
|
Moss, B.,
O. Elroy-Stein,
T. Mizukami,
W. A. Alexander, and T. R. Fuerst.
1990.
New mammalian expression vectors.
Nature
348:91-92[Medline].
|
| 22.
|
Oba, D. E., and L. M. Hutt-Fletcher.
1988.
Induction of antibodies to the Epstein-Barr virus glycoprotein gp85 with a synthetic peptide corresponding to a sequence in the BXLF2 open reading frame.
J. Virol.
62:1108-1114[Abstract/Free Full Text].
|
| 23.
|
Osterreider, N.,
A. Neubauer,
C. Brandmuller,
B. Braun,
O.-R. Kaaddden, and J. Baines.
1996.
The equine herpesvirus type 1 glycoprotein gp21/22a, the herpes simplex virus type 1 gM homolog, is involved in virus penetration and cell-to-cell spread of virions.
J. Virol.
70:4110-4115[Abstract].
|
| 24.
|
Pilling, A.,
A. J. Davison,
E. Telford, and D. Meredith.
1994.
The equine herpesvirus type 1 glycoprotein homologous to herpes simplex virus type 1 glycoprotein M is a major constituent of the virus particle.
J. Gen. Virol.
75:439-442[Abstract/Free Full Text].
|
| 25.
|
Pulford, D. J.,
P. Lowrey, and A. J. Morgan.
1995.
Co-expression of the Epstein-Barr virus BXLF2 and BKRF2 genes with a recombinant baculovirus produces gp85 on the cell surface with antigenic similarity to the native protein.
J. Gen. Virol.
76:3145-3152[Abstract/Free Full Text].
|
| 26.
|
Pyles, R. B.,
N. M. Sawtell, and R. L. Thompson.
1992.
Herpes simplex virus type 1 dUTPase mutants are attenuated for neurovirulence, neuroinvasiveness, and reactivation from latency.
J. Virol.
66:6706-6713[Abstract/Free Full Text].
|
| 27.
|
Ross, J.,
M. Williams, and J. I. Cohen.
1997.
Disruption of the varicella-zoster virus dUTPase and the adjacent ORF9A gene results in impaired growth and reduced syncytia formation in vitro.
Virology
234:186-195[Medline].
|
| 28.
|
Takada, K.
1984.
Cross-linking of cell surface immunoglobulin induces Epstein-Barr virus in Burkitt lymphoma lines.
Int. J. Cancer
33:27-32[Medline].
|
| 29.
|
Varki, A.
1998.
Factors controlling the glycosylation potential of the Golgi apparatus.
Trends Cell Biol.
8:34-40.
[Medline] |
| 30.
|
Wang, X., and L. M. Hutt-Fletcher.
1998.
Epstein-Barr virus lacking glycoprotein gp42 can bind to B cells but is not able to infect.
J. Virol.
72:158-163[Abstract/Free Full Text].
|
| 31.
|
Yaswen, L. R.,
E. B. Stephens,
L. C. Davenport, and L. M. Hutt-Fletcher.
1993.
Epstein-Barr virus glycoprotein gp85 associates with the BKRF2 gene product and is incompletely processed as a recombinant protein.
Virology
195:387-396[Medline].
|